A Novel Strategy to Produce CAR‐γδ T Cells via Site‐Directed Gene Integration by a Combination of CRISPR/Cas9 and AAV
Ruoyu Dong, Yixi Zhang, Guangxun Yuan, Xiaoyan Yue, Yingying Ding, Xun Zeng, Haowen Xiao · 2026
Read A Novel Strategy to Produce CAR‐γδ T Cells via Site‐Directed Gene Integration by a Combination of CRISPR/Cas9 and AAV by Ruoyu Dong, Yixi Zhang, Guangxun Yuan, Xiaoyan Yue, Yingying Ding, Xun Zeng, Haowen Xiao (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13181432.txt.
Description
CAR T cell therapy rewires a patient's own immune cells to hunt cancer, but the usual cell type has limits. Ruoyu Dong and six co-authors describe a way in 2026 to build the therapy on gamma-delta T cells instead, which sense tumors without the usual identity checks.
The team used CRISPR cutting plus a virus delivery step to slot the CAR gene into one exact address in the cell's DNA. That address, the delta chain locus, meant the native receptor was knocked out at the same time. Tuning the delivery settings made the swap efficient. The finished cells released cytokines, killed tumor cells in dishes, kept growing well, and shrank tumors in mice while extending their survival.
Catalog record
| CREATOR | Ruoyu Dong, Yixi Zhang, Guangxun Yuan, Xiaoyan Yue, Yingying Ding, Xun Zeng, Haowen Xiao |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 40 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |